1. Recent Articles

    1. Radiolabeling and initial biological evaluation of [(18)F]KBM-1 for imaging RAR-α receptors in neuroblastoma.

      Radiolabeling and initial biological evaluation of [(18)F]KBM-1 for imaging RAR-α receptors in neuroblastoma.

      Bioorg Med Chem Lett. 2017 Feb 01;:

      Authors: Solingapuram Sai KK, Das BC, Sattiraju A, Almaguel FG, Craft S, Mintz A

      Abstract Retinoic acid receptor alpha (RAR-α) plays a significant role in a number of diseases, including neuroblastoma. Children diagnosed with high-risk neuroblastoma are treated13-cis-retinoic acid, which reduces risk of cancer recurrence.

      Read Full Article
      Mentions: Imaging
    2. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consort

      Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium.

      Lancet Oncol. 2017 Feb;18(2):e75-e90

      Read Full Article
    3. Pregnancy in survivors of childhood cancer may confer elevated risk for cardiotoxicity

      Pregnancy may be linked to an increased risk for cardiotoxicity in patients who survived cancer in childhood, according to a research letter published in the Journal of the American College of Cardiology.Using data from The University of Texas MD Anderson Cancer Center, Kara A. Thompson, MD, from the department of cardiology at the University of Texas, Houston, and colleagues evaluated the cardiac outcomes of childhood cancer survivors who were pregnant and who were previously exposed to anthracyclines and/or chest radiation.

      Read Full Article
    4. Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma.

      Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma.

      Oncotarget. 2017 Feb 11;:

      Authors: Florea AM, Varghese E, McCallum JE, Mahgoub S, Helmy I, Varghese S, Gopinath N, Sass S, Theis FJ, Reifenberger G, Büsselberg D

      Abstract Neuroblastoma (NB) is a pediatric cancer treated with poly-chemotherapy including platinum complexes (e.g. cisplatin (CDDP), carboplatin), DNA alkylating agents, and topoisomerase I inhibitors (e.g. topotecan (TOPO)).

      Read Full Article
    5. Prevalence of cardiovascular late sequelae in long-term survivors of childhood cancer: A systematic review and meta-analysis

      Cardiovascular diseases are well-known late effects of childhood cancer and research on these late effects is a highly important emerging field. We conducted a systematic review with a meta-analysis to give an overview of the current evidence and the prevalence of late cardiovascular events.

      Read Full Article
    6. Prominent Pulmonary Metastases Without Concurrent Osseous Involvement in Patients With High-Risk Neuroblastoma.

      Prominent Pulmonary Metastases Without Concurrent Osseous Involvement in Patients With High-Risk Neuroblastoma.

      Clin Nucl Med. 2017 Feb 13;:

      Authors: Bai X, Zhuang H

      Abstract Metastases from high-risk neuroblastomas generally are to the bone or bone marrow. Multiple lung metastases are rare, especially when there was no concurrent osseous metastasis. We report 2 cases of high-risk neuroblastomas having prominent lung metastases without concurrent osseous lesion observed.

      Read Full Article
    7. Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy

      Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating signals and maintains the antitumor response, has elicited a remarkable clinical response in certain cancer patients. However, intrinsic resistance (i.e., insensitivity of the tumors to therapy) remains a daunting challenge. The efficacy of ICBT is tightly modulated by the function of each step in the antitumor immunity cycle. Mechanistically, the number of mutations determines tumor immunogenicity.

      Read Full Article
    8. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.

      Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.

      Genome Med. 2017 Feb 10;9(1):15

      Authors: Duffy DJ, Krstic A, Halasz M, Schwarzl T, Konietzny A, Iljin K, Higgins DG, Kolch W

      Abstract BACKGROUND: Retinoid therapy is widely employed in clinical oncology to differentiate malignant cells into their more benign counterparts.

      Read Full Article
      Mentions: MYCN
    9. Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Oncotarget. 2017 Feb 08;:

      Authors: Singhal SS, Singhal S, Singhal P, Singhal J, Horne D, Awasthi S

      Abstract Neuroblastoma, a rapidly growing yet treatment responsive cancer, is the third most common cancer of children and the most common solid tumor in infants. Unfortunately, neuroblastoma that has lost p53 function often has a highly treatment-resistant phenotype leading to tragic outcomes.

      Read Full Article
      Mentions: Treatment MYCN
    10. Artificial neural network classifier predicts neuroblastoma patients' outcome.

      Artificial neural network classifier predicts neuroblastoma patients' outcome.

      BMC Bioinformatics. 2016 Nov 08;17(Suppl 12):347

      Authors: Cangelosi D, Pelassa S, Morini M, Conte M, Bosco MC, Eva A, Sementa AR, Varesio L

      Abstract BACKGROUND: More than fifty percent of neuroblastoma (NB) patients with adverse prognosis do not benefit from treatment making the identification of new potential targets mandatory.

      Read Full Article
      Mentions: Treatment
    11. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells.

      Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells.

      Clin Cancer Res. 2017 Feb 09;:

      Authors: Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM

      Read Full Article
    12. Metastatic neuroblastoma diagnosed on prenatal sonographic examination performed for decreased fetal movement.

      Metastatic neuroblastoma diagnosed on prenatal sonographic examination performed for decreased fetal movement.

      J Clin Ultrasound. 2017 Feb 09;:

      Authors: Chapa HO, Geddie SG, Flores R

      Abstract We report a case of fetal neuroblastoma presenting with massive liver metastasis diagnosed during the biophysical profile sonographic examination performed for decreased fetal movement. The patient presented at 37 weeks' gestation with limited fetal movement over 24 hours.

      Read Full Article
      Mentions: Metastasis
    13. Neuroblastoma treatment in the post-genomic era.

      Neuroblastoma treatment in the post-genomic era.

      J Biomed Sci. 2017 Feb 08;24(1):14

      Authors: Esposito MR, Aveic S, Seydel A, Tonini GP

      Abstract Neuroblastoma is an embryonic malignancy of early childhood originating from neural crest cells and showing heterogeneous biological, morphological, genetic and clinical characteristics.

      Read Full Article
      Mentions: Treatment ALK MYCN
    14. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (9 articles) Treatment
    2. (4 articles) Metastasis
    3. (4 articles) MYCN
    4. (3 articles) Immunotherapy
    5. (2 articles) ALK
  3. Recent Quotes

    1. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    2. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    3. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    4. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    5. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    6. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    7. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    8. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    9. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju
    10. The dBET1 and the dFKBP12 compounds are presently in a late stage of lead optimization for therapeutic development in both cancer and non-malignant diseases, Composition-of-matter and method-of-use patent applications have been filed on these and other additional targeted agents, as well as on the chemistry platform.
      By Prem Das